Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, $0.01 par value
-
Shares outstanding
-
4,043,321
-
Total 13F shares
-
61,766
-
Share change
-
+35,939
-
Total reported value
-
$181,057
-
Price per share
-
$2.94
-
Number of holders
-
15
-
Value change
-
+$105,526
-
Number of buys
-
4
-
Number of sells
-
7
Institutional Holders of BriaCell Therapeutics Corp. - Common Stock, $0.01 par value (BCTX) as of Q2 2025
As of 30 Jun 2025,
BriaCell Therapeutics Corp. - Common Stock, $0.01 par value (BCTX) was held by
15 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
61,766 shares.
The largest 10 holders included
SABBY MANAGEMENT, LLC, UBS Group AG, Federation des caisses Desjardins du Quebec, Royal Bank of Canada, GROUP ONE TRADING LLC, NATIONAL BANK OF CANADA /FI/, SBI Securities Co., Ltd., TD Waterhouse Canada Inc., RAYMOND JAMES FINANCIAL INC, and Allworth Financial LP.
This page lists
15
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.